Biogen (BIIB) Tops Q4 EPS by 34c, Offers FY20 Guidance

Biogen (NASDAQ: BIIB) reported Q4 EPS of $8.34, $0.34 better than the analyst estimate of $8.00. Revenue for the quarter came in at $3.67 billion versus the consensus estimate of $3.54 billion.

GUIDANCE:

Biogen sees FY2020 EPS of $31.50-$33.50, versus the consensus of $33.03. Biogen sees FY2020 revenue of $14-14.3 billion, versus the consensus of $14.06 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Rubico to shift from semi-annual to quarterly financial reporting
• Credo Technology shares rise on analyst support and conference comments